TIGIT and cancer: Different from immunotherapies based on adoptive T cell therapy and immune-checkpoint inhibitors (ICI, designed to target the immune-inhibitory receptors CTLA-4, PD1 and TIGIT on T cells), conventional which are designed to target the immune-inhibitory receptors CTLA-4, PD1 and TIGIT on T cells, conventional cyto-ablative cancer therapies (i.e. chemotherapy and radiotherapy) directly target the tumor cell.